Jeff Ingersoll and the Practitioner Testing Model Behind GI-MAP
Why Diagnostic Solutions Lab's GI-MAP represents a practical model for microbiome-informed functional testing.
Jeff Ingersoll's public career footprint is closely tied to Diagnostic Solutions Lab. In the Rational Wellness episode featuring Jeff and Val Prisecaru, Jeff is introduced as President of Diagnostic Solutions Lab, the company behind the GenomicInsight profile and the GI-MAP stool test.
For practitioners, GI-MAP is one of the more relevant parts of that story. Diagnostic Solutions Lab describes GI-MAP, the GI Microbial Assay Plus, as a comprehensive stool test that uses quantitative polymerase chain reaction, or qPCR, to detect parasites, bacteria, H. pylori, fungi, and more by targeting organism-specific DNA.
Why qPCR matters in practice
Diagnostic Solutions Lab emphasizes quantification as a core advantage of GI-MAP. The clinical question is not only whether an organism is detected; it is also whether the level appears trace, meaningful, or elevated enough to shape treatment priority. The company describes qPCR as a method that can provide true quantitative values and help differentiate trace organism levels from frank elevations that may indicate active infection.
Microbiome testing as clinical workflow
GI-MAP also reflects a larger shift in functional and precision medicine. Stool testing has moved beyond a generic gut-health snapshot toward a practitioner workflow that can include pathogen detection, H. pylori virulence factors, bacterial balance, fungi, parasites, antibiotic resistance genes, inflammation-related markers, and metabolite add-ons such as bile acids and short-chain fatty acids.
From a Studio23 perspective, the key insight is operational. A microbiome test is only as useful as the practitioner workflow around it: ordering, collection, interpretation, patient conversation, intervention, and retesting. Jeff's association with Diagnostic Solutions Lab is relevant because the company's testing model is explicitly practitioner-facing rather than purely consumer-facing.
What this means for Studio23 practitioners
- Dynamic data: unlike the genome, the microbiome changes with diet, medication, stress, infection, and intervention.
- Retesting value: microbiome testing can support longitudinal care by showing whether a protocol changed the biological terrain.
- Clinical translation: quantitative results are most useful when they help practitioners prioritize decisions instead of simply listing organisms.
Related public sources
Related Articles
Genomic Insight: How Jeff Ingersoll and Val Prisecaru Brought Practitioner Genomics Into Clinical Use
Val Prisecaru: Nutrigenomics, Microbiome Analysis, and the Practitioner as Translator
